Impact of cardiac radiation dose on survival in esophageal cancer patients
Impact of Dose to Cardiac Substructures on Survival in Patients With Esophageal Cancer Treated With Radiotherapy or Chemoradiotherapy
This study is trying to see how different amounts of radiation to specific parts of the heart affect survival in patients with non-operable esophageal cancer who are receiving treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest) |
| Trial ID | NCT05996276 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how the dose of radiation delivered to specific cardiac substructures affects survival rates in patients with non-operable esophageal cancer undergoing radiotherapy or chemoradiotherapy. It seeks to integrate dosimetric parameters related to cardiac sub-structures into clinical practice, moving beyond the traditional approach of considering the heart as a whole. By analyzing these parameters, the study hopes to identify factors that could improve patient outcomes in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with localized or locally advanced esophageal cancer treated with radiotherapy or chemoradiotherapy.
Not a fit: Patients who have undergone upfront surgery for their esophageal cancer or those with metastatic disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates for esophageal cancer patients by optimizing radiation treatment plans to minimize cardiac toxicity.
How similar studies have performed: While the study focuses on a specific population, previous research has shown that considering dosimetric parameters related to cardiac substructures can improve outcomes in other cancer types, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically or cytologically proven esophageal cancer * Localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy * Tumor dose ≥ 50 Gy * Non-opposition of living patients formulated * Patient affiliated to a social security scheme Exclusion Criteria: * Age \< 18 years * Patient treated with upfront surgery * Tumor dose \< 50 Gy * Other concomitant neoplasia * Metastatic patient * Refusal to participate * Patient under legal protection (guardianship, curatorship, etc...)
Where this trial is running
Brest
- Chu Brest — Brest, France (Recruiting)
Study contacts
- Principal investigator: Vincent Bourbonne, MD, PhD — Radiation Oncology Department, Brest University Hospital
- Study coordinator: Vincent BOURBONNE, MD, PhD
- Email: vincent.bourbonne@chu-brest.fr
- Phone: +33298223398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.